At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Apr 20, 2026 at 16:38 ET
Three key insiders at United Therapeutics, including CEO Martine Rothblatt, CFO James Edgemon, and Director Christopher Patusky, collectively sold $2.46 million in open-market transactions over a 7-day period. The sales follow routine derivative exercises, with Patusky accounting for 67% of the total dollar volume. Total open-market proceeds represent just 0.01% of the company's $25.1B market cap.
- CEO Martine Rothblatt sold $948,381 in open-market transactions across three dates (2026-04-20 to 2026-04-22).
- Director Christopher Patusky sold $1,655,790 in shares on 2026-04-24, following full exercise of options.
- CFO James Edgemon sold $503,649 in shares on 2026-04-20 after exercising 10,000 options.
- All sales were preceded by option exercises; no insider made a net open-market sale without prior exercise.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access